AGL 37.99 Decreased By ▼ -0.03 (-0.08%)
AIRLINK 210.70 Increased By ▲ 13.34 (6.76%)
BOP 9.56 Increased By ▲ 0.02 (0.21%)
CNERGY 6.36 Increased By ▲ 0.45 (7.61%)
DCL 9.25 Increased By ▲ 0.43 (4.88%)
DFML 37.70 Increased By ▲ 1.96 (5.48%)
DGKC 98.55 Increased By ▲ 1.69 (1.74%)
FCCL 36.15 Increased By ▲ 0.90 (2.55%)
FFBL 88.94 Increased By ▲ 6.64 (8.07%)
FFL 13.95 Increased By ▲ 0.78 (5.92%)
HUBC 129.11 Increased By ▲ 1.56 (1.22%)
HUMNL 13.79 Increased By ▲ 0.29 (2.15%)
KEL 5.45 Increased By ▲ 0.13 (2.44%)
KOSM 7.30 Increased By ▲ 0.30 (4.29%)
MLCF 45.39 Increased By ▲ 0.69 (1.54%)
NBP 60.55 Decreased By ▼ -0.87 (-1.42%)
OGDC 219.99 Increased By ▲ 5.32 (2.48%)
PAEL 40.85 Increased By ▲ 2.06 (5.31%)
PIBTL 8.47 Increased By ▲ 0.22 (2.67%)
PPL 198.50 Increased By ▲ 5.42 (2.81%)
PRL 40.15 Increased By ▲ 1.49 (3.85%)
PTC 27.60 Increased By ▲ 1.80 (6.98%)
SEARL 108.12 Increased By ▲ 4.52 (4.36%)
TELE 8.60 Increased By ▲ 0.30 (3.61%)
TOMCL 36.00 Increased By ▲ 1.00 (2.86%)
TPLP 13.74 Increased By ▲ 0.44 (3.31%)
TREET 24.38 Increased By ▲ 2.22 (10.02%)
TRG 61.15 Increased By ▲ 5.56 (10%)
UNITY 34.25 Increased By ▲ 1.28 (3.88%)
WTL 1.69 Increased By ▲ 0.09 (5.63%)
BR100 12,045 Increased By 318.3 (2.71%)
BR30 37,342 Increased By 965.5 (2.65%)
KSE100 112,625 Increased By 3111.4 (2.84%)
KSE30 35,529 Increased By 1015.3 (2.94%)

The European Commission has approved Novartis' Entresto drug for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction, the Swiss drugmaker said on Tuesday. Entresto is the first new drug in decades for helping patients whose lives are in danger because their hearts cannot pump blood efficiently. Analysts estimate it could have annual sales of some $5.4 billion by 2020.

Copyright Reuters, 2015

Comments

Comments are closed.